We assessed focal therapy eligibility in men who underwent multiparametric magnetic resonance imaging and targeted biopsy with correlation to whole mount histology after radical prostatectomy. Materials and Methods: Subjects were selected from among the 454 men in whom targeted biopsy proven prostate cancer was derived from regions of interest on multiparametric magnetic resonance imaging from 2010 to 2016. Focal therapy eligibility was limited to a maximum Gleason score of 4 þ 3 in regions of interest with or without other foci of low risk prostate cancer (Gleason score 3 þ 3 and less than 4 mm). Men who did not meet NCCNÒ intermediate risk criteria were classified as ineligible for focal therapy. Of the 454 men 64 underwent radical prostatectomy and biopsy findings were compared to final pathology findings. Results: Of the 454 men with a biopsy proven region of interest 175 (38.5%) were eligible for focal therapy. Fusion biopsy, which combined targeted and template biopsy, had 80.0% sensitivity (12 of 15 cases), 73.5% specificity (36 of 49) and 75.0% accuracy (48 of 64) for focal therapy eligibility. Targeted cores alone yielded 73.3% sensitivity (11 of 15 cases), 47.9% specificity (23 of 48) and 54.7% accuracy (35 of 64). Gleason score and extension across the midline differed in 4 and 9, respectively, of the 13 cases that showed discordant biopsy and whole mount histology. Conclusions: Using intermediate risk eligibility criteria more than a third of men with a targeted biopsy proven lesion identified on multiparametric magnetic resonance imaging would have been eligible for focal therapy. Eligibility determined by fusion biopsy was concordant with whole mount histology in 75% of cases. Improved selection criteria are needed to reliably determine focal therapy eligibility.
FOCAL therapy has the potential to improve CaP management by reducing the side effects associated with radical treatment. While the safety and feasibility of FT strategies have been reported using cryoablation, 1 focal laser ablation 2 and high intensity focused US, 3 to our knowledge long-term oncologic efficacy is unknown. A critical barrier to robust testing of FT strategies is appropriate patient selection criteria, which are not clearly established. 4, 5 A recent FDA (Food and Drug Administration), AUA (American Urological Association) and SUO (Society of Urologic Oncology) workshop on partial gland ablation highlighted this challenge, noting that "some [authors] regard [partial gland ablation] as an alternative to AS for low risk cancers, whereas others view it as an alternative to radical therapy for selected, higher risk cancers." 6 Regardless of approach there is broad agreement on the importance of assessing for FT using mpMRI followed by targeted biopsy. 6 To clarify the impact of different patient selection criteria on FT eligibility we retrospectively studied men who underwent MRI/US fusion biopsy, incorporating targeted and template biopsies. To confirm biopsy findings and derive the accuracy of fusion biopsy for FT eligibility we examined whole organ concordance of eligibility assessment in a subset of patients who underwent radical prostatectomy. 7 
METHODS

Study Cohort
All men who underwent MRI/US fusion biopsy at UCLA between January 2010 and January 2016 were retrospectively screened for a suspicious lesion identified on mpMRI (UCLA or PI-RADSÔ, version 2 score of 3 to 5 regions of interest), which was found to contain CaP at targeted biopsy ( fig. 1 ). We applied FT eligibility criteria based on the NCCN (National Comprehensive Cancer NetworkÒ) intermediate risk definition 8 and recent consensus guidelines (see Appendix).
6 Figure 2 shows histological profiles for FT eligible patients based on biopsy, including 3 CaP patterns, of which each was suitable for treatment with hemigland ablation or less. Men with biopsy negative ROIs were considered ineligible for FT. Similarly men without csCaP (Gleason score 3 þ 3 and MCCL less than 4 mm) were also considered ineligible 9 regardless of the number of positive cores. All clinical data were collected prospectively in a UCLA institutional review board approved registry. The study received UCLA institutional review board approval.
Magnetic Resonance Imaging/Ultrasound Guided Targeted Biopsy
The fusion biopsy method, which was previously described, was unchanged throughout the study period. 10, 11 Briefly, within 2 months of biopsy patients underwent 3 Tesla mpMRI with a body coil. MRI was interpreted under the direction of a dedicated uroradiologist (DJAM) and suspicious lesions were assessed according to UCLA and PI-RADS criteria. 10, 12 MRI assessment was based on the UCLA assessment system, 10 which predates PI-RADS, version 1. After PI-RADS, version 2 was established, MRI was assessed according to each system using the highest suspicion category found. At biopsy images were registered and fused with real-time transrectal ultrasound using a NoblusÒ device to generate a 3D image of the prostate with delineated ROIs.
Targeted and template cores were obtained by a single urologist (LSM) at UCLA Clark Urology Center using an ArtemisÔ MRI/US fusion and biopsy tracking device with the patient under local anesthesia. 11 A dedicated uropathologist (JH) interpreted all biopsy cores.
Focal Therapy Strategy Assessment
FT eligibility was assessed using 3 ablative strategies (site specific, quadrant and hemigland) to determine the extent of ablation that would be needed to eliminate the index lesion. The strategies were based on the location of cancer containing biopsy cores in relation to the ROI. Individual biopsy cores from each subject were assessed by PostgreSQLÔ, version 9.0 database software to determine eligibility for each strategy. Men with positive biopsy cores limited to the ROI were considered eligible for all FT strategies (site specific, quadrant and hemiablation). Men with positive cores adjacent to the ROI were considered eligible for the quadrant and hemiablation strategies. Those with ipsilateral but distant positive cores (ie in a different quadrant) were considered eligible for hemiablation. Figure 3 shows the strategies. We evaluated eligibility using a threshold of GS 4 þ 3 or less and GS 3 þ 4 or less (table 1) .
Radical Prostatectomy Specimen Whole Mount Processing
Of the 454 men with biopsy positive ROI 64 underwent RP and whole mount processing to facilitate MRI-histological correlation as previously described. 7 Three-dimensional printed molds were used in cases processed after 2014. Lesion contours identified on whole mount histology were loaded in custom software and elastically warped to match the mpMRI defined prostate contour, allowing for targets on mpMRI to be directly compared to lesions identified on whole mount histology. Eligibility for FT was then reassessed based on evaluation of the whole mount sections by a dedicated urological pathologist (JH).
Statistical Analysis
Descriptive statistics of patient characteristics were calculated for each group. CIs were calculated using a binomial assumption at a 95% threshold. Kruskal-Wallis nonparametric 1-way ANOVA and post hoc tests were used to measure differences between continuous variables. Pearson chi-square tests were performed on categorical variables. Statistical significance was considered at p <0.05 for all analyses. Statistical analyses were done . Differences between inclusion criteria are expected but nonetheless post hoc tests showed an increasing trend across all 3 categories (low risk ineligible, eligible and high risk ineligible) with total PSA, PSA density, number of positive cores and maximum cancer core length.
Of the patients with GS 3 þ 4 or less 154 (33.9%) were eligible for hemiablation or less, 140 (30.8%) were eligible for quadrant ablation or less and 94 (20.7%) were eligible for site specific ablation. A total of 175 men (38.5%) were eligible for hemiablation or less, 157 (34.6%) were eligible for quadrant ablation or less and 105 (23.1%) were eligible for site specific ablation when inclusion criteria included those with maximum GS 4 þ 3 (table 1) . No man in this study was known to have undergone focal therapy.
In this series 64 men underwent RP as first line therapy with whole mount processing of the specimen, including 35 (54.7%) with 3D printed molds. Average AE SD time from biopsy to surgery was 89.1 AE 32.5 days. Figure 3 shows examples of whole mount histology and 3D digital reconstruction. Of the 64 patients who underwent RP 25 would have qualified for FT based on biopsy findings and 15 qualified for FT based on whole mount histological findings with 16 discordant findings (table 2). Of the 13 patients who were classified as eligible for FT based on fusion biopsy and who did not qualify based on whole mount (false-positive results) 4 were discordant due to a higher GS on whole mount findings and 9 were discordant due to a lesion crossing the midline. When examining factors associated with eligibility determined after RP, no significant difference was found for PSA density (p ¼ 0.31), prostate volume (p ¼ 0.32) or total serum PSA (p ¼ 0.09). However, the study was not powered to analyze whole mount prostatectomy cases.
Targeted and template biopsy combined had 80.0% sensitivity, 73.5% specificity and 75.0% accuracy to determine eligibility for FT compared to the whole mount gold standard. Targeted cores alone yielded 73.3% sensitivity (11 of 15 cases) and 47.9% specificity (23 of 48) with 54.7% accuracy (35 of 64).
DISCUSSION
FT has recently emerged as a potentially definitive treatment for localized CaP which aims to preserve quality of life. 13 FT appeared promising in initial studies using high intensity focused US, cryotherapy and focal laser ablation 14 but to our knowledge long-term oncologic control has not been established. One key barrier is knowing a priori which patients will benefit from partial treatment. 6 Some groups have argued for FT as an alternative to surgical intervention and others for FT as a complement to active surveillance. 15 While the multifocality of CaP favors whole gland treatment, studies have emphasized the importance of the index lesion as a driver of metastatic potential. 16, 17 Recent series indicated that low grade, low volume lesions behave in indolent fashion and have limited metastatic potential. 18, 19 Contrasting these studies is a case report by Haffner et al, who investigated the clonal origin of lethal prostate cancer and found that it arose from a small, low grade cancer focus in the primary tumor. 20 Nevertheless, more recent and larger studies have continued to support the concept that CaP is driven by a single clone 21 and can be serially tracked by biomarkers and targeted biopsy. 22 Furthermore, FT has been done successfully to treat other multifocal solid organ malignancies of which secondary lesions proved to be indolent. 23 In the current study we estimated the proportion of men diagnosed by MRI/US fusion biopsy who would be eligible for FT. We used eligibility criteria from a recent FDA, AUA and SUO workshop on partial gland ablation. 6 Biopsy findings were also compared to whole mount histology findings in a subset of cases. Of the men in whom cancer was confirmed by MRI targeted and fusion biopsy 38.5% were suitable candidates for FT and 23.1% met the criteria for site specific ablation.
Fusion biopsy findings were 75% concordant with whole mount findings in agreement with previous findings. 24 Nine of the 13 false-positive results were attributable to a lesion that crossed the midline. In this study we considered lesions that crossed the midline by even a few millimeters as ineligible for any method of focal therapy. In practice many of these lesions can be treated with site specific ablation or hockey stick ablation as described by Ahmed et al. 25 Only in 4 of 25 cases did assessment through targeted biopsy fail due to upgrading. While study eligibility criteria included GS 4 þ 3 or less lesions, 89% of patients met more stringent criteria, limited to GS 3 þ 4 less.
The increased sensitivity of MRI targeted biopsy to detect csCaP, which has been widely reported in other situations, 24, 26, 27 also appeared valuable when evaluating for FT eligibility. In our work more than half of eligible men had csCaP localized in a single ROI while 40% had csCaP outside the index lesion.
Targeted and template biopsies were important to accurately classify patients for FT. Overall accuracy using the 2 methods was improved by 20% over that of targeted biopsy alone (54% vs 75%). This suggests that the combined targeted and template biopsy approach is effective for ruling out focal therapy. While whole mount histology of RP specimens is generally concordant with targeted biopsy findings, 24 the moderate agreement in eligibility assessment indicates that improved criteria must be established. On univariate analysis of eligible and ineligible patients PSA density significantly differed among the 3 cohorts. While RP data did not show a similar significant difference in PSA density (p ¼ 0.08), the difference suggests that PSA density merits further investigation as an eligibility criterion in a larger powered study.
While a potential source of error is the registration accuracy between MRI and US, which is about 3 mm, 11, 28 a larger issue is the underestimation of the true tumor burden by MRI. In 52 eligible patients (29.7%) csCaP was ipsilateral and adjacent to the ROI, qualifying for quadrant ablation. Le Nobin et al found that tumors required a 1 cm margin to achieve complete treatment 29 while Priester et al reported that the average uniform margin to achieve complete treatment exceeded 1.5 cm. 7 This supports the notion that biopsy cores should be taken from beyond the margins of the ROI when evaluating for site specific or quadrant based FT. Moreover, these data suggest customization of focal therapy based on data from individual biopsy site locations around the apparent tumor margin. 30 This also suggests that perhaps improved criteria for FT would include individual consideration of the position and size of the lesion, ie patient specific planning, rather than uniform classification.
Several limitations exist that preclude a more general interpretation of our findings. This study was hypothesis generating and retrospective in nature, and it was performed at a single site with all biopsies done by a single physician. Limited data were available to compare fusion biopsy findings with whole mount histology results. Nevertheless, the significant concordance between the 2 approaches to determining FT candidacy suggests that fusion biopsy may serve as an important aid to determine eligibility. Further, these results might be used to develop a framework for future prospective studies.
The current findings suggest that 1) more than a third of the patients with a biopsy proven target (MRI suspicion score 3 or greater) were eligible for FT using consensus criteria and 2) fusion biopsy with targeting and template samples accurately characterizes the grade and extent of CaP for the purpose of determining FT eligibility.
CONCLUSIONS
More than a third of men with prostate cancer in a MRI defined region of interest were found to be eligible for focal therapy using intermediate risk criteria to determine eligibility. MRI/US fusion biopsy using targeting and template biopsies provided concordance with whole mount histology to determine focal therapy eligibility. Improved criteria are needed to determine FT eligibility with accuracy.
APPENDIX
Focal therapy eligibility criteria based on NCCN intermediate risk definition 8 and recent consensus guidelines 6 Eligibility criteria: Clinical stage T2c or less Serum PSA 20 ng/ml or less ROI on mpMRI grade 3 or greater csCaP in mpMRI derived ROI, defined as GS 4 þ 3 or less in any core or GS 3 þ 3 with MCCL 4 mm or greater At least 10 template and 2 targeted cores obtained demonstrating unilateral csCaP Ineligible:
Clinical stage T3a or greater Serum PSA greater than 20 ng/ml GS greater than 4 þ 3 CaP in any core Bilateral csCaP (GS 3 þ 3 and MCCL 4 mm or greater, or any GS 3 þ 4 or greater) Absence of csCaP
